Blackfynn’s multidisciplinary team of experts with their extensive knowledge about neurology has built a state-of-the-art data integration and analysis platform to improve the therapeutics for neurological diseases. Blackfynn’s data platform integrates medical and scientific data of all types to enable rapid exploration of data relationships and dynamic data visualizations to address complex scientific and clinical questions.
Blackfynn’s platform captures the knowledge related to raw data and the relationships that exist across it with metadata and presents a holistic view of all the data including EEG, radiology, pathology, and genomics.
By individualizing the device for each patient, we can offer better quality of life and better therapeutic outcomes
The platform is integrated with real-time analysis tools, which empower biotech and pharmaceutical experts to dynamically identify patterns in integrated datasets and create patient cohorts, visualize disease progression, and develop novel biomarkers. The company’s extensive API and client libraries allow biotech and pharma organizations to build custom applications and integrate that with their existing workflows and processes. Built securely from the ground up, Blackfynn safeguards the data in a compliant manner and provides access to the tools based on customers’ requirement.
Typically, most of the devices used in the treatment of neurological diseases are limited by their large size, lack of specificity and inability to respond in real time to the changing therapeutic needs of patients. In addition, it is difficult to predict which patients will get better, and which may get worse using device therapy. Blackfynn addresses these intricacies by providing the infrastructure that allows organizations to use therapeutics in a personalized way for each patient. By analyzing integrated data from patient populations over time, it may be possible to predict which patients will benefit most from device therapy before they undergo risky surgical procedures. “By individualizing the device for each patient, we can offer better quality of life and better therapeutic outcomes,” emphasizes Amanda Christini, Co-Founder & President of Blackfynn.
Continuing on its mission to challenge the status quo of the neurology space, Blackfynn is committed to supporting and accelerating basic and translational research in academia. Consistent with this mission, Blackfynn will be launching a tailored version of the platform that meets the exact needs and pricing requirements of academic researchers. Blackfynn is rapidly becoming the standard data platform for the neuroscience academia and has collaborations in place with several institutions. They include Marinus Pharmaceuticals, the Epilepsy Study Consortium, the NIH Stimulating Peripheral Activity to Relieve Conditions (SPARC) program, the Children’s Hospital of Philadelphia (CHOP), DARPA, NIDA and dozens of academic labs and institutions worldwide.